Zacks: Analysts Expect MediWound Ltd. (MDWD) to Post -$0.19 Earnings Per Share
Equities analysts expect that MediWound Ltd. (NASDAQ:MDWD) will report ($0.19) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for MediWound’s earnings, with estimates ranging from ($0.20) to ($0.17). MediWound reported earnings of ($0.26) per share during the same quarter last year, which indicates a positive year over year growth rate of 26.9%. The firm is scheduled to announce its next quarterly earnings report on Monday, November 13th.
On average, analysts expect that MediWound will report full year earnings of ($0.76) per share for the current year, with EPS estimates ranging from ($0.81) to ($0.70). For the next year, analysts expect that the company will report earnings of ($0.65) per share, with EPS estimates ranging from ($0.85) to ($0.48). Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow MediWound.
A number of equities analysts recently commented on MDWD shares. Jefferies Group LLC set a $10.00 target price on MediWound and gave the company a “buy” rating in a report on Friday, August 25th. Cowen and Company started coverage on MediWound in a report on Thursday, September 28th. They set an “outperform” rating and a $9.00 target price for the company. ValuEngine raised MediWound from a “strong sell” rating to a “sell” rating in a research report on Friday, October 20th. Oppenheimer Holdings, Inc. set a $10.00 price target on MediWound and gave the company a “buy” rating in a research report on Tuesday, October 17th. Finally, Zacks Investment Research raised MediWound from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a research report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $9.15.
Hedge funds have recently bought and sold shares of the business. Migdal Insurance & Financial Holdings Ltd. raised its position in MediWound by 20.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after purchasing an additional 342,165 shares in the last quarter. Wells Fargo & Company MN raised its position in MediWound by 19.7% in the 1st quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 8,745 shares in the last quarter. Nationwide Fund Advisors acquired a new stake in MediWound in the 3rd quarter valued at about $1,538,000. Finally, Renaissance Technologies LLC raised its position in MediWound by 1.7% in the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 1,300 shares in the last quarter. 20.64% of the stock is currently owned by institutional investors.
MediWound (NASDAQ:MDWD) opened at $4.57 on Friday. MediWound has a twelve month low of $4.25 and a twelve month high of $8.25.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.